Analyst Ratings for Marinus Pharma
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Marinus Pharma (NASDAQ:MRNS) stock. The company has an average price target of $21.4, a decrease of 17.69% from the previous average price target of $26.00.
August 11, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Marinus Pharma's average price target has decreased by 17.69% to $21.4, according to 5 analysts' opinions over the past 3 months.
The decrease in the average price target suggests that analysts are less optimistic about the future performance of Marinus Pharma's stock, which could negatively impact its short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100